Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka - people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In our pharmaceutical business, that focus is on our core therapeutic areas of the central nervous system and oncology, exploring unresolved challenges faced by patients and aiming to develop innovative solutions that bring new value. Together with our continued efforts to expand the market share of new antipsychotic drugs such as REXULTI and ABILIFY MAINTENA, we will continue with our research and development for patients with Alzheimer's dementia, who are said to number more than 30 million worldwide.
Otsuka Pharmaceutical Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. Otsuka group companies employed 45,000 people and had consolidated sales of approximately USD 11 billion (EUR 9.9 billion) in 2016.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka Pharmaceutical at www.otsuka.co.jp/en/.
« Go Back